Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.31 |
| ▸ | CPT2 | P23786 | 2/20 | 0.31 |
| ▸ | CPT1A | P50416 | 2/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.31 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.31 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.31 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.31 |
| ▸ | FPR2 | P25090 | 1/20 | 0.31 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3595199 | 0.94 | GRIN1 (0.34) | KDM4EIRAK4GRIN1GRIN2BCPT2 | |
| SCHEMBL3592264 | 0.88 | CPT1A (0.33) | KDM4EGRIN1GRIN2BCPT2CPT1A | |
| SCHEMBL3582566 | 0.88 | GRIN2B (0.33) | KDM4EIRAK4GRIN1GRIN2BCPT2 | |
| SCHEMBL3588834 | 0.87 | GRIN1 (0.35) | KDM4EIRAK4GRIN1GRIN2BCPT2 | |
| SCHEMBL3581627 | 0.85 | IRAK4 (0.33) | KDM4EIRAK4GRIN1GRIN2BCPT2 | |
| SCHEMBL3576368 | 0.85 | KDM4E (0.35) | KDM4EGRIN1GRIN2BCPT2CPT1A | |
| SCHEMBL13031295 | 0.85 | GRIN2B (0.34) | GRIN1GRIN2B | |
| SCHEMBL3583149 | 0.85 | IRAK4 (0.32) | KDM4EIRAK4GRIN2BCPT2CPT1A | |
| SCHEMBL3589601 | 0.85 | CPT1A (0.33) | IRAK4GRIN1GRIN2BCPT2CPT1A | |
| SCHEMBL3593480 | 0.85 | CPT1A (0.35) | KDM4ECPT2CPT1AGABRA1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | MERCK SHARP & DOHME CORP. | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | CXCR3, CXCR1, CXCR2 | KDM4E 3447/4885IRAK4 367/4885GRIN1 571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.